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Abstract
Purpose—This study was designed to test whether metabolic characterization of intact, unaltered
human rectal adenocarcinoma specimens is possible using the high-resolution magic angle spinning
proton (1H) magnetic resonance spectroscopy technique.
Methods—The study included 23 specimens from five patients referred for ultrasonographic
staging of suspected rectal cancer. Multiple biopsies of macroscopically malignant rectal tumors and
benign rectal mucosa were obtained from each patient for a total of 14 malignant and 9 benign
samples. Unaltered tissue samples were spectroscopically analyzed. Metabolic profiles were
established from the spectroscopy data and correlated with histopathologic findings.
Results—Metabolomic profiles represented by principle components of metabolites measured from
spectra differentiated between malignant and benign samples and correlated with the volume percent
of cancer (P=0.0065 and P=0.02, respectively) and benign epithelium (P=0.0051 and P=0.0255,
respectively), and with volume percent of stroma, and inflammation.
Conclusions—Magnetic resonance spectroscopy of rectal biopsies has the ability to metabolically
characterize samples and differentiate between pathological features of interest. Future studies should
determine its utility in in vivo applications for non-invasive pathologic evaluations of suspicious
rectal lesions.
Keywords
Rectal cancer; Metabolomics; Diagnosis; Magnetic resonance spectroscopy
Rectal cancers account for approximately one-third of colorectal malignancies, and the
estimated number of cases for 2008 is 40,740.1 The expected overall five-year survival rate
for patients with a diagnosis of rectal cancer is 65 percent in the United States, according to
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tthe National Cancer Institute.2 Despite known prognostic factors and new and improved
diagnostic methods, the severity of cancer stage is frequently underestimated.3 Accurate
diagnosis, staging, and management of the disease are crucial for achieving optimal outcomes.
Currently, although histopathologic evaluation of biopsy samples can achieve most of these
goals, radiologic tests such as computed tomography (CT), ultrasonography (US), positron
emission tomography (PET), and magnetic resonance imaging (MRI) are unable to
differentiate malignant from benign tissue with sufficient accuracy to be clinically useful for
noninvasive diagnosis. The preoperative staging of the tumor is usually done according to the
TNM system by using MRI, endorectal US, CT, or a combination of these tests to assess the
tumor itself, whether it has spread to locoregional lymph nodes, and whether distant metastases
are present.4, 5
The diagnosis of rectal cancer is currently dependent on biopsies taken from the suspicious
lesion during colonoscopic or sigmoidoscopic examinations. Although histopathology will
remain the standard for the diagnosis of rectal cancer for years to come, it is desirable to develop
new technologies that not only can detect suspicious sites on direct biopsy, but may even
replace histopathology to achieve diagnosis and grading of rectal cancer tumors noninvasively
in vivo. Feasible techniques currently being examined for their potential roles in cancer
management are those that probe the underlying biochemistry accompanying malignant
changes, such as magnetic resonance spectroscopy (MRS). High-resolution magic angle
spinning (HRMAS) proton (1H) MRS is one such technique developed for the metabolomic
analysis of intact tissues.6, 7 The HRMAS 1HMRS technique allows acquisition of highly
resolved spectra from unaltered tissue samples, while preserving tissue histopathologic
architecture for histopathologic analysis. Since its development, several groups, including our
own, have shown the ability of this technique to differentiate malignant from benign samples
of various tissues and to accurately characterize the bioactivity and, therefore aggressiveness,
of tumors.8, 9 The aim of the present study was to test the efficacy of the HRMAS 1HMRS
technique in differentiating malignant rectal cancer from benign cells by measuring the
metabolic profile of rectal tumor biopsy samples and comparing them with benign rectal
mucosa samples from the same patients.
Patients and Methods
Patients
Patients referred for ultrasonographic staging of suspected rectal cancer at the University of
Minnesota were asked to participate in the study. The first five patients who agreed to
participate were included in the pilot cohort reported here. Written informed consent to obtain
ultrasonography-guided multiple biopsies from the tumor and benign rectal mucosa was
obtained. Approval from the Institutional Review Board of the University of Minnesota was
obtained before study initiation.
Biopsy samples
Biopsies of untreated rectal lesions that appeared malignant on US examination and on
macroscopic examination with rigid sigmoidoscopy were obtained from each patient. One to
two biopsies from macroscopically benign rectal mucosa were also obtained from each patient
by inserting biopsy forceps through the rigid sigmoidoscope. The biopsy samples were
immediately stored in cryo vials, de-identified (blinded), labeled, and put on dry ice. The
samples were stored at −70°C until shipped overnight, on dry ice, to the Massachusetts General
Hospital for spectroscopy and quantitative histopathology analyses.
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Spectral analysis was performed on an Avance spectrometer (Bruker, Billerica, MA) operating
at 600 MHz (14.1 T). Tissue samples were placed in a 4-mm rotor with plastic inserts creating
a spherical sample space of ∼10 ml located at the center of the detection coil. Approximately
2.0 µl of D2O was added into the rotor with the tissue sample for field locking. All spectroscopy
measurements were carried out at 4°C for tissue preservation. A repetition time of five seconds
with 32 transients was used to acquire each spectrum. Spectra were collected with spinning
rates of 3600 Hz. A rotor-synchronized Carr–Purcell–Meiboom–Gill (CPMG) filter (10 ms)
was included in the pulse sequence to reduce broad resonances associated with probe and rotor
background or macromolecules.
Spectroscopic data were processed with commercial software (Nuts, Acorn NMR Livermore,
CA). All free induction decays were subjected to 1-Hz apodization before Fourier
transformation, baseline correction, and phase adjustments of both zero and first order.
Resonance intensities reported here represent integrals of curve-fittings with Lorentzian-
Gaussian line shapes. Each sample produced well-resolved spectra with more than 50
quantifiable metabolites or regions. The 25 most intense resonance peaks were normalized by
the total spectral intensity of the metabolite region up-field from water resonance (0.5∼4.5
ppm), and then selected for further statistical analyses. All spectra were processed manually
and objectively, without knowledge of tissue pathologic information.
Histopathology
After spectroscopic measurements were made, the samples were formalin fixed, embedded in
paraffin, cut into 5-µm sections, and stained with hematoxylin and eosin. Sets of serial sections
cut 150 µm apart were obtained from each sample. Percentages of the major pathologic
components (cancer, benign epithelium, stroma, and inflammation) were visually estimated
by a pathologist, and percentage of volume was calculated using a BX41 Microscope Imaging
System (Olympus, Melville, NY), in conjunction with the image analyzer MicroSuite (Soft
Imaging System, Lakewood, CO), as previously described.8
Statistical Analysis
Principle component analysis (PCA) was used to test the hypothesis that different pathologic
components have differing metabolite profiles. This method was used to identify spectral
metabolite profiles that correlated with pathologic features of the tissue, such as percentages
of volume consisting of malignant cells, benign epithelium, stromal cells, and inflammation.
An illustration of the PCA process can be found in Figure 1. The metabolite matrix was
simplified such that 25 spectral regions with intensity means above the median determined
from means calculated for all regions were subjected to PCA with statistical software JMP®
(SAS Institute, Cary, NC). Principle component analysis identifies combinations of metabolites
whose standardized concentrations (the difference between the particular intensity of the
concerned metabolite for a particular sample and the mean intensity normalized by the standard
deviation, both calculated for the metabolite from the entire sample set) are indicative of
changes in the matrix that likely result from pathologic differences present among the analyzed
samples. The principle components (PCs) consist of individual loading factors for each spectral
region that are unique to the principle component and that indicate the extent to which the
metabolites within that region are associated with the process described by the principle
component. Thus, principle components are independent of one another.
The first seven principle components (with eigenvalues >1.0) were subjected to paired
Student’s t tests to investigate the ability of each component to differentiate malignant from
benign samples. Simple linear regression analysis was used to test for correlations, with
principle component scores as explanatory variables and pathologic features (volume
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variables.
Results
In this pilot study, a total of 23 samples were collected from five patients and analyzed. The
results of histopathologic examination are shown in Table 1. Macroscopically, 14 samples were
judged malignant and 9 benign. Histologic examination showed that samples from four patients
(cases 2–5) had been correctly categorized on the basis of macroscopy as being malignant
tissue or benign mucosa; samples deriving from suspected cancerous tissue from one patient
(case 1) did not contain malignant cells.
Comparison of malignant vs. benign tissue samples showed significant differences for the three
principle components, as listed in Table 2, together with their eigenvalues, percentages of
variances represented, and cumulative percentages of variances. In addition to this binary
differentiating capacity, linear regression analysis showed several principle components had
predictive value, summarized in Table 3. For instance, PC 2, accounted for 16.1 percent of the
variance among the samples, correlated negatively with volume percentage of malignant tissue
(P=0.0065, slope=−0.0966, Pearson’s Correlation coefficient r=−0.550) and positively with
volume percentage of normal epithelium (P=0.0051, slope=0.0367, and r=0.564)‥
The major loading factors for the regions that most significantly correlated with variations
described by the principle components are shown in Table 4. For instance, PC 2 reflected
changes in several metabolites with known connections to oncologic developments, including
choline and phosphocholine.10 Metabolic activity, including choline metabolites in the spectral
region from 3.20 to 3.24 ppm, which significantly contributed to the differentiation of the
normal from cancerous profile established by PC 2, is shown for one pair of samples (tumor
and benign from patient 3) in Figure 2.
As indicated by Table 4, the most significant loading factors of each principle component, i.e.,
those with larger “+” or “-” values, present the positive or negative contributions of the
concerned metabolites represented by their corresponding standardized concentration. For
example, if the linear regression fit for a principle component with cancer is negative (slope<0),
a negative loading factor for the choline metabolites in the 3.20- to 3.24-ppm region suggests
that elevation of these metabolites above the calculated mean from all samples, and the
reduction of metabolites in the 3.63–3.65 ppm region from their mean, contributes to the
malignant profile, as seen with PC 2 in Table 4.
Discussion
Metabolomics and the HRMAS 1HMRS Technique
The HRMAS 1HMRS technique is an advanced metabolomics methodology. Metabolomics is
the science of examining the unique chemical fingerprint of a cell, tissue, or organ by measuring
the global variation of metabolites present (the metabolome). The metabolome may represent
dynamic and physiologic changes that take place at the cellular level and that manifest
themselves as changes in metabolite concentrations before pathologic changes can be seen on
a static histologic slide. In this way, metabolomics offers a means by which malignant potential
may be quantified before the malignancy changes the cellular architecture. This hypothesis is
the basis of what can be described as oncologic metabolomics. The HRMAS 1HMRS technique
was developed specifically for the analysis of intact, unaltered tissue samples. This deviates
from classical NMR of aqueous solutions and other magnetic resonance techniques, which
require that metabolites be extracted from the tissue of interest, destroying the tissue and
precluding histopathologic analysis. The histopathology is crucial, however, as it allows
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the presence or absence of malignant cells). The utility of the HRMAS 1HMRS method is
further increased by its ability to be automated and free from issues of inter-observer
reproducibility.
Differentiation of Cancerous from Benign Samples
Currently, histopathologic examination can reliably differentiate benign from malignant
tissues for clinical diagnosis and was the standard used in this pilot study. We used
histopathologic validation to determine whether metabolite profiles for human rectal
adenocarcinoma biopsy samples constructed with HRMAS 1HMRS in the same manner as that
created for various other tissues might have the potential to improve the current state of
radiology for noninvasive in vivo rectal adenocarcinoma diagnosis. Each of the four pathologic
features examined (malignant cells, benign epithelium, stromal cells, and inflammation)
manifested different biochemical changes that could be significantly delineated by PCA. The
principle components that correlated with volume percentages of tumor or benign mucosa were
most noteworthy.
Interestingly different principle components that correlated with the same process could have
metabolite regions that contributed to the process in the same manner but with differing
magnitudes, or they could have metabolite regions that contributed in different ways. For
example, increases in metabolites in the 3.41- to 3.47-ppm region were related to the malignant
condition for both PC 2 and PC6). However, metabolites in the 3.66- to 3.68-ppm region
significantly contributed to PCs 2 and 6, but in opposite ways (diminished in the malignant
condition in PC2, but elevated in the malignant condition in PC6).
The sensitivity of the current profiles may be limited by the mixed pathological features in the
analyzed samples. By incorporating a larger cohort of samples and additional features, the
metabolite profiles might be further refined.
Implications and Limitations of the Current Study
Results from the current study are encouraging because they show that metabolic differences
between samples containing different pathologic features can be significant enough to be
measurable with HRMAS 1HMRS. Such results have important implications for future
research, particularly if additional features such as tumor grade or aggressiveness are found to
manifest themselves in measurable metabolic differences. If further investigations are able to
correlate clinical features with metabolic profiles, HRMAS 1HMRS may be very useful for
rectal adenocarcinoma, and may provide information that current in vivo radiologic means are
unable to produce. One such factor of paramount clinical importance is tumor virulence, as
defined by the likelihood of recurrence following curative surgery. Our examinations of human
prostate cancer indicate metabolic profiles can subdivide similarly staged malignancies into
groups according to aggressiveness of the primary tumor.8 Although the current study, which
was at the pilot level and therefore recruited only 5 subjects, is by no means an indication that
such segregation of rectal tumors is possible with HRMAS 1HMRS, it does suggest that future
examinations toward this end are a valid undertaking. Because our subjects were recruited
before treatment, the clinical outcomes are not known at this time and cannot be correlated
with the metabolic information gathered.
Furthermore, given the potential of MRS-based metabolomic profiles in differentiating
malignancy from benign tissues from the same patients, the ever increasing developments in
the in vivo MR technologies may make it possible to use the present ex vivo techniques in
vivo, and to inspire further technology developments targeted at investigations of in vivo
noninvasive MRS in the detection and characterization of human rectal adenocarcinomas.
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tConclusion
As an exploratory study designed to test of the efficacy of the HRMAS 1HMRS method in
metabolically characterizing human rectal adenocarcinomas, the current results are significant
and encouraging. The results indicate that magnetic resonance may be useful in the ex vivo
biochemically classification of tissue samples as malignant or benign. In addition to the
possibility of future in vivo use, further studies may reveal whether HRMAS 1HMRS, can
accurately stage rectal tumors or indicate additional prognostic factors, such as a subset of more
aggressive tumors that should be monitored postsurgery for recurrence.
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tFigure 1.
Illustration of principal component analysis (PCA). This process starts with the top S-P matrix,
where S and P represent samples and spectral peaks, respectively, and p#,# is the value of the
standardized peak concentration. Standardized concentration refers to the difference between
the particular intensity of the concerned metabolite for a particular sample and the mean
intensity normalized by the standard deviation, with both mean and standard deviation values
calculated for the metabolite from the entire sample set. From this S-P matrix, the PCA process
generates a principal component (PC) coefficient matrix (bottom) to be used to form PCs of
linear combinations of the standardized peak concentrations. All PCs are orthogonal to each
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tother, with PC1 representing the greatest and PC23, the least changes in the standardized peak
concentrations.
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tFigure 2.
A) HRMAS 1HMRS spectrum of Patient 3, sample ii (benign mucosa); entire metabolite
spectrum (top) and enlargement of the 3.2–3.7 ppm area, which significantly contributed to
the variation in PC 2; B) Sample 3-i contained 0 percent malignant cells, 70 percent benign
epithelium, 20 percent stromal tissue, and 10 percent inflammation; C) Spectrum from Patient
3, sample iv (tumor tissue), entire spectrum (top) and enlargement of the 3.2–3.7 ppm area;
D). Sample 3 iv contained 20 percent malignant cells, 0 percent benign epithelium, 60 percent
stromal tissue, and 20 percent inflammation.
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Table 3
Results of linear regression analysis
Feature (% sample volume) P value Slope Pearson ’s Correlation
coefficient (r)
PC 2
    Cancer 0.0065 −0.0966 −0.550
    Benign epithelium 0.0051 0.0367 0.564
PC 4
    Benign epithelium 0.0333 0.0240 0.445
    Stroma 0.0311 −0.0343 −0.451
PC 6
    Cancer 0.0200 0.0494 0.482
    Benign epithelium 0.0255 −0.0177 −0.465
PC 7
    Inflammation 0.0026 −0.0418 −0.598
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Table 4
Loading factors and regions corresponding to principle components
Loading factor Region (ppm)
PC 2 (correlates negatively with cancer and positively with benign epithelium)
0.36331 3.65–3.63
0.36085 3.58–3.51
0.35388 3.68–3.66
0.22815 1.15–1.14
−0.35014 4.21–4.16
−0.32501 3.29–3.25
−0.28986 3.47–3.41
−0.2086 3.24–3.20
PC 4 (correlates positively with benign epithelium and negatively with stroma)
0.29915 1.15–1.14
0.25695 1.36–1.28
0.25598 2.16–2.05
0.24953 3.62–3.59
0.24475 4.09–4.06
0.24294 0.92–0.84
0.1987 2.04–1.96
0.16453 3.24–3.20
0.16375 3.92–3.88
−0.4325 1.02–0.93
−0.30164 3.87–3.83
−0.28619 4.04–3.96
−0.26181 1.49–1.47
PC 6 (correlates positively with cancer and negatively with benign epithelium)
0.36361 3.47–3.41
0.32365 2.40–2.34
0.27615 3.68–3.66
0.24947 2.48–2.41
0.24394 4.15–4.11
−0.45242 4.09–4.06
−0.28916 3.95–3.93
PC 7 (correlates positively with inflammation)
0.21691 3.29–3.25
0.20066 3.24–3.20
0.18972 3.80–3.75
0.18171 2.48–2.41
0.13947 3.65–3.63
0.13223 0.92–0.84
0.11239 4.04–3.96
−0.7542 4.15–4.11
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PC = principle component; ppm = parts per million.
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